Want to see NL:VVY full AI Analyst Report?
VVY Stock Chart & Stats
€1.12
€0.02(1.27%)
At close: 4:00 PM EDT
€1.12
€0.02(1.27%)
Day’s Range― - ―
52-Week Range€0.82 - €1.68
Previous CloseN/A
Volume2.70K
Average Volume (3M)36.40K
Market Cap
€25.47M
Enterprise Value€29.61M
Total Cash (Recent Filing)€2.45M
Total Debt (Recent Filing)€76.00K
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Dec 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding29,614,338
10 Day Avg. Volume63,151
30 Day Avg. Volume36,402
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)8.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage limits mandatory debt-service demands and reduces exposure to interest costs or refinancing pressure. Although the company remains financially constrained, its capital structure does not add substantial creditor risk, preserving some flexibility as clinical programs advance.
Reduced Annual LossThe substantial year-over-year reduction in net loss indicates that the pace of earnings deterioration moderated in 2025. If maintained, better cost control could extend the company’s operating runway and make future financing needs less severe, even though profitability remains negative.
Focused Oral Drug PipelineAn orally available small-molecule approach gives Vivoryon a defined therapeutic platform and a lead focus in a major neurodegenerative disease area. The related enzyme-modulation capabilities may also support additional programs beyond the lead candidate over time.
Bears Say
No Recent Operating RevenueThe absence of reported revenue in the two latest periods shows that the company has not yet established a recurring commercial revenue base. Continued losses therefore depend on successful development, partnering, or financing rather than internally funded product sales.
Persistent Cash BurnPersistently negative operating and free cash flow means current activities do not fund themselves. Even with lower operating cash burn in 2025, ongoing outflows can consume available resources and increase reliance on external funding or further balance-sheet contraction.
Shrinking Financial BaseThe sharp decline in equity and total assets signals that losses and cash consumption have materially reduced the company’s financial resources. A smaller capital base limits resilience and leaves less capacity to absorb setbacks or sustain development without new funding.
Vivoryon Therapeutics AG News
VVY FAQ
What was Vivoryon Therapeutics AG’s price range in the past 12 months?
Vivoryon Therapeutics AG lowest stock price was €0.82 and its highest was €1.68 in the past 12 months.
What is Vivoryon Therapeutics AG’s market cap?
Vivoryon Therapeutics AG’s market cap is €25.47M.
When is Vivoryon Therapeutics AG’s upcoming earnings report date?
Vivoryon Therapeutics AG’s upcoming earnings report date is Dec 03, 2026 which is in 38 days.
How were Vivoryon Therapeutics AG’s earnings last quarter?
Vivoryon Therapeutics AG released its earnings results on Aug 06, 2026. The company reported -€0.114 earnings per share for the quarter.
Is Vivoryon Therapeutics AG overvalued?
According to Wall Street analysts Vivoryon Therapeutics AG’s price is currently Overvalued.
Does Vivoryon Therapeutics AG pay dividends?
Vivoryon Therapeutics AG does not currently pay dividends.
What is Vivoryon Therapeutics AG’s EPS estimate?
Vivoryon Therapeutics AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivoryon Therapeutics AG have?
Vivoryon Therapeutics AG has 29,614,338 shares outstanding.
What happened to Vivoryon Therapeutics AG’s price movement after its last earnings report?
Vivoryon Therapeutics AG reported an EPS of -€0.114 in its last earnings report. Following the earnings report the stock price went up 2.5%.
Which hedge fund is a major shareholder of Vivoryon Therapeutics AG?
Currently, no hedge funds are holding shares in NL:VVY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivoryon Therapeutics AG
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel treatments for Alzheimer's disease. The company's therapeutic pipeline primarily focuses on mitigating Alzheimer's by targeting and preventing the formation of toxic pyroglutamate-Abeta (pGlu-Abeta). Its flagship compound, PQ912, a small molecule QC inhibitor, has successfully concluded Phase IIb clinical trials for both Alzheimer's disease and various cancer indications. Additionally, Vivoryon is advancing PQ1565, another small molecule (a glutaminyl-peptide cyclotransferase-like inhibitor), through preclinical development, specifically for cancer therapy. Beyond its small molecule programs, the company is also developing a monoclonal antibody designed to improve the clearance of pGlu-Abeta from the body. To bolster its research and development efforts, Vivoryon has forged several key partnerships, including collaborations with the University Medical Center Schleswig-Holstein for cancer immunotherapy discovery, Nordic Bioscience for the clinical progression of PQ912 in Alzheimer's, and the Fraunhofer Institute for cell therapy and immunology. Furthermore, a significant regional licensing agreement with Simcere Pharmaceutical Group Ltd. aims to develop and commercialize treatments for Alzheimer's disease by targeting the neurotoxic amyloid species N3pE (pGlu-Abeta). Established in 1997, Vivoryon Therapeutics N.V. maintains its headquarters in Halle, Germany.
Technical Analysis
Pharming Group
―
Avantium N.V.
―
Corbion NV
―
Lakefront Biotherapeutics NV
―
DSM-Firmenich AG
―